19632943Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, Pennella EJ, Girvan AC, Guba SCClinical lung cancerAntineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Lung NeoplasmsAntibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carboplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Glutamates; Guanine; Humans; Paclitaxel; Pemetrexed; Prognosis; Treatment OutcomeTreatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2009 Jul; 10(4):252-6.Clin Lung Cancer2009-07-01T00:00:002009Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.Faculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD018572Concepts & Ideas531750.95367Disease-Free SurvivalD000911Chemicals & Drugs642580.8984Antibodies, MonoclonalD005971Chemicals & Drugs7170.991318GlutamatesD018450Physiology1907870.790832Disease ProgressionD016896Concepts & Ideas36434750.519213Treatment OutcomeD006147Chemicals & Drugs5110.996933GuaninePhilipBonomiPhilip Bonomi349183Bonomi, PhilipProfessorD016190Chemicals & Drugs17490.983623Carboplatin4ProfessorAuthorship 76222D061067Chemicals & Drugs411130.922308Antibodies, Monoclonal, Humanized0.0899920.0899921authors10.2517has subject areaD017239Chemicals & Drugs22740.972772PaclitaxelRush University, Rush Medical CollegeD002289Disorders253160.769548Carcinoma, Non-Small-Cell LungD000971Procedures542900.853586Antineoplastic Combined Chemotherapy ProtocolsD004334Concepts & Ideas842230.947666Drug Administration ScheduleInternal Medicine, Division of Hematology/Oncology/Cell TherapyD011379Procedures2048390.798443Prognosistrue1ProfessorProfessorD008175Disorders646250.65394Lung NeoplasmsD006801Living Beings643293340.211949HumansD0000682588270.990946BevacizumabD0000684374140.993958Pemetrexed